|Molar mass||244.38 g mol−1|
|Except where noted otherwise, data are given for|
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references
It was an intermediate compound in the development of the successful anti-ulcer drug cimetidine (Tagamet®).
Development of metiamide from burimamide
- addition of a sulfide group close to the imidazole ring, giving thiaburimamide
- addition of methyl group to the 4- position on the imidazole ring to favour the tautomer of thiaburimamide which binds better to the H2-receptor
- is 10 times more potent than burimamide
- inhibited histamine-stimulated release of gastric acid
- increased healing rate of peptic ulcers
- provided symptomatic relief for ulcerous patients.
- in clinical trials, an unacceptable number of patients dosed with metiamide developed agranulocytosis (decreased white blood cell count)
- clinical trials aborted, as patients were left susceptible to infection
Modification of metiamide to cimetidine
- with =O or =NH resulted in a compound with much less activity (20 times less than metiamide)
- however, the NH form (the guanidine analogue of metiamide) did not show agonistic effects
- to prevent the guanidine group being protonated at physiological pH, electron-withdrawing groups were added
- adding a -C≡N or -NO2 group prevented the guanidine group being protonated and did not cause agranulocytosis
The nitro and cyano groups are sufficiently electronegative to reduce the pKa of the neighbouring nitrogens to the same acidity of the thiourea group, hence preserving the activity of the drug in a physiological environment.
- the -C≡N group (part of a cyanoguanidine moiety) was a little more effective
- it was developed and marketed as cimetidine,
- Clayden, J. Greeves, N. Warren, S. Wothers, P. (2001). Organic Chemistry. Oxford. ISBN 0-19-850346-6